Aveo/Astellas’ Tivozanib Bests Nexavar, Barely, In Advanced Kidney Cancer

Aveo/Astellas’ triple VEGF inhibitor tivozanib hit its progression-free survival endpoint of superiority over Onyx/Bayer’s Nexavar (sorafenib), but the question remains whether a three-month PFS advantage can confer first-line market superiority.